ARCAPTA NEOHALER
LOE ApproachingNDAINHALATIONPOWDER
Approved
Jul 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARCAPTA NEOHALER is an inhaled powder formulation approved in 2011 for chronic respiratory disease management. The specific indication and mechanism of action are not publicly detailed in available sources, but the inhalation route targets pulmonary delivery. This small-molecule product represents Novartis's respiratory portfolio in the long-acting maintenance category.
LOE Approaching2.2 years to LOE
Product is in late-stage maturity with LOE expected by October 2028; commercial teams should anticipate resource reallocation and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on ARCAPTA NEOHALER at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.